Holen Sie sich die Stockscreener-App
30.64
8.67%
-2.91
Vorhandelsmarkt:
30.99
0.35
+1.14%
Schlusskurs vom Vortag:
$33.55
Offen:
$33.57
24-Stunden-Volumen:
1.12M
Relative Volume:
2.63
Marktkapitalisierung:
$2.35B
Einnahmen:
$13.17M
Nettoeinkommen (Verlust:
$-199.06M
KGV:
-11.18
EPS:
-2.74
Netto-Cashflow:
$-156.53M
1W Leistung:
-12.21%
1M Leistung:
-17.23%
6M Leistung:
-24.12%
1J Leistung:
-27.29%
1-Tages-Spanne:
$30.58
$33.64
1-Wochen-Bereich:
$30.58
$35.45
52-Wochen-Spanne:
$30.58
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Firmenname
Xenon Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 484-3300
Adresse
200 - 3650 GILMORE WAY, BURNABY
Vergleichen Sie XENE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
30.64 | 2.35B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-01-04 | Eingeleitet | Citigroup | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-04-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-14 | Eingeleitet | Goldman | Buy |
| 2022-12-12 | Eingeleitet | Cowen | Outperform |
| 2022-11-28 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-19 | Eingeleitet | Raymond James | Outperform |
| 2022-08-29 | Eingeleitet | BofA Securities | Buy |
| 2022-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-21 | Eingeleitet | Needham | Buy |
| 2020-06-01 | Fortgesetzt | Jefferies | Buy |
| 2020-03-25 | Eingeleitet | Wedbush | Outperform |
| 2020-01-08 | Eingeleitet | William Blair | Outperform |
| 2019-09-20 | Eingeleitet | Guggenheim | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2017-03-13 | Eingeleitet | Jefferies | Buy |
| 2016-10-21 | Eingeleitet | Stifel | Buy |
| 2016-09-26 | Eingeleitet | Guggenheim | Buy |
| 2016-04-14 | Bestätigt | Jefferies | Buy |
| 2015-10-30 | Fortgesetzt | Jefferies | Buy |
| 2014-12-02 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Xenon Pharmaceuticals Inc Aktie (XENE) Neueste Nachrichten
Xenon Pharmaceuticals Enters Oversold Territory (XENE) - Nasdaq
Thrivent Financial for Lutherans Sells 12,394 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Teacher Retirement System of Texas Acquires 2,994 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
StockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to Hold - Defense World
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Bought by Swiss National Bank - Defense World
(XENE) Trading Advice - news.stocktradersdaily.com
Xenon Pharmaceuticals announces executive changes - MSN
Bank of New York Mellon Corp Sells 2,294 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) - Defense World
What is William Blair’s Estimate for XENE Q1 Earnings? - Defense World
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals at Stifel Forum: Strategic Advances in CNS By Investing.com - Investing.com Canada
Xenon Pharmaceuticals’ CCO Departure and Consultancy Role - MSN
(XENE) Trading Signals - Stock Traders Daily
Xenon Pharmaceuticals to Present at Stifel 2025 Virtual CNS Forum - TipRanks
Xenon to Present at Stifel 2025 Virtual CNS Forum - The Manila Times
Xenon Pharmaceuticals Reveals Latest Progress on Revolutionary CNS Drug Development - Stock Titan
Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of “Buy” by Brokerages - Defense World
Traders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - Defense World
Xenon Pharmaceuticals appoints PwC as new auditor - Investing.com
Xenon Pharmaceuticals appoints PwC as new auditor By Investing.com - Investing.com South Africa
New KCNQ2/3 activators disclosed in Xenon Pharmaceuticals patents - BioWorld Online
Q1 Earnings Forecast for XENE Issued By HC Wainwright - Defense World
Equities Analysts Offer Predictions for XENE Q1 Earnings - Defense World
What is Leerink Partnrs’ Estimate for XENE Q1 Earnings? - Defense World
(XENE) On The My Stocks Page - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) Hits New 1-Year Low – Time to Sell? - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Earns “Outperform” Rating from William Blair - Defense World
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus - MSN
Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
HC Wainwright Has Pessimistic Outlook of XENE Q1 Earnings - MarketBeat
Strategic Growth Potential and Upcoming Catalysts Drive Buy Rating for Xenon Pharmaceuticals - TipRanks
Xenon Pharmaceuticals price target lowered to $42 from $43 at Wedbush - TipRanks
Investor Network: Xenon Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
RBC Capital Adjusts Xenon Pharmaceuticals Price Target to $58 From $56, Maintains OutperformSpeculative Risk Rating - Marketscreener.com
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $60 From $67, Maintains Buy Rating - Marketscreener.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2024 Earnings Call Transcript - Insider Monkey
Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Xenon Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Xenon Pharmaceuticals Advances Clinical Pipeline Amid Financial Losses - TipRanks
Xenon Pharmaceuticals reports Q4 EPS (84c), consensus (84c) - TipRanks
Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com
Xenon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xenon Pharmaceuticals Q4 Net Loss Widens -February 27, 2025 at 05:13 pm EST - Marketscreener.com
Earnings Flash (XENE) Xenon Pharmaceuticals Q4 Loss Per Share $-0.84 vs. FactSet Est Loss $-0.88 - Marketscreener.com
Xenon Pharmaceuticals: Q4 Earnings Snapshot -February 27, 2025 at 04:20 pm EST - Marketscreener.com
Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update - The Manila Times
Xenon Pharmaceuticals Inc. Announces Resignation of Sherry Aulin as Chief Financial Officer, Effective June 30, 2025 - Marketscreener.com
Finanzdaten der Xenon Pharmaceuticals Inc-Aktie (XENE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.89%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):